

الجمهورية اللبنانية
وزارة الصحة العامة
المديرية العامة

رقم المحفوظات: ١٧/٢٠١٥
بيروت في ٧ تشرين الأول ٢٠١٥

قرار رقم ١/٣.٨٤

سحب جميع المستحضرات و المستلزمات الطبية المصنعة من قبل شركة Silimed
من الاسواق اللبنانية ومنع استيرادها و تداولها

ان وزير الصحة العامة

بناء على المرسوم رقم ١١٢١٧ تاريخ ٢٠١٤/٢/١٥.

بناء على قانون مزاوله مهنة الصيدلة رقم ٣٦٧ تاريخ ١٩٩٤/٨/١.

بناء على كتاب مستودع ادوية شركة ديما هيلث- كير ش.م.م المسجل في قلم مصلحة الصيدلة تحت رقم ٣٤٧٧٣ تاريخ ٢٠١٥/٩/٣٠ و المتعلق بتعليق اجازة التسويق لجميع المستحضرات و المستلزمات الطبية المصنعة من قبل شركة Silimed- البرازيل ، المسجلة في لبنان و المرفق بكتاب من شركة Silimed و التي تطلب بموجبه تعليق طوعي لبيع هذه المستحضرات ، وذلك بعد ان تم الكشف على وجود : particules à " la surface des implants mammaires"

بناء على قرار ال ANSM (Agence nationale de sécurité du médicament et des produits de santé) الصادر بتاريخ ٢٠١٥/٩/٢٤ و المتعلق بتعليق تسويق المستحضرات و المستلزمات الطبية المصنعة من قبل شركة Silimed لا سيما:

(Implants mammaires , testiculaires ,fessiers ,de mollets ,de pectoraux et de la face

بناء على قرار ال AFMPS (Agence fédérale des médicaments et des produits de santé) الصادر بتاريخ ٢٠١٥/٩/٢٤ و المتعلق بتعليق تسويق المستحضرات و المستلزمات الطبية المصنعة من قبل شركة Silimed - البرازيل ،

بناء على مطالعة مصلحة الصيدلة

بناء على استطلاع رأي مدير العناية الطبية

بناء على اقتراح مدير عام الصحة العامة

ذرة الباصم
والمشاريع

و حرصا على السلامة العامة،

يقرر ما يأتي:

المادة الأولى: تسحب جميع المستحضرات والمستلزمات الطبية المصنعة من قبل شركة Silimed من الاسواق اللبنانية ويمنع استيرادها و تداولها.

المادة الثانية: يكلف التفتيش الصيدلي تنفيذ مضمون هذا القرار.

المادة الثالثة: يبلغ هذا القرار حيث تدعو الحاجة.

وزير الصحة العامة

وائل أبو فاعور



طبق الأصل

يبلغ:

- منظمة الصحة العالمية
- الصندوق الوطني للضمان الاجتماعي
- نقابة صيادلة لبنان
- نقابة الاطباء في بيروت والشمال
- نقابة اصحاب المستشفيات
- نقابة مستوردي الادوية واصحاب المستودعات
- مديرية العناية الطبية
- التفتيش الصيدلي في مصالح الصحة في المحافظات
- دائرة البرامج و المشاريع
- دائرة المعلوماتية
- الموقع الالكتروني في وزارة الصحة العامة

Medical Device Alert

MDA/2015/034

Issued: 25 September 2015 at 16:00

Implantable medical devices manufactured by SILIMED - Industria de Implantes Ltda

Summary

Temporary suspension of the CE certificate due to particles found on some devices.

Action

- Do not implant/use affected devices
- Quarantine devices
- Await further advice from the distributor(s) and/or the MHRA
- If patients enquire they can be reassured that this situation is being investigated as a matter of priority with our European counterparts to decide on further action. However, if they would like to be kept up-to-date they can register for [email updates](#) and they will be kept informed.

Action by

- Implanting surgeons

Deadlines for actions

Actions underway: 02 October 2015

Actions complete: 09 October 2015

Device details

The following devices distributed in the UK by EuroSurgical are affected:

- silicone implants for plastic surgery: breast implants, pectoral implants, gluteal implants, calf implants, implants for hand surgery, tissue expanders, facial implants, nostril retainers, suspension sheets for breast surgery
- silicone invasive devices: sizers for silicone implants
- silicone implants for general surgery: blocks and sheets

The following devices distributed in the UK by Genesis Medical are affected:

- implants for urology: testicular implants, penile implants, vaginal stents and periurethral constrictors

Problem / background

The German medical device regulatory authority informed MHRA on Friday 18 September 2015 that a German notified body had temporarily suspended the marketing and distribution of all medical devices manufactured by Silimed Industria de Implantes Ltda.

A recent inspection of the manufacturing facility by the notified body identified particles on the surface of some devices.

MHRA is investigating in collaboration with other European regulators and recommends that none of these devices should be implanted until further advice is issued.

Distributor contacts

Eurosurgical Ltd
Morrow Business Park
Guildford
Surrey
GU4 7WA

Tel: 01483 456 007

Email: sales@eurosurgical.co.uk

Genesis Medical Ltd
7 Trojan Business Park
Cobbold Road
London NW10 9ST
Tel: 020 8451 4100

Email: avia@genmedhealth.com

Distribution

If you are responsible for cascading these alerts in your organisation, these are our suggested distribution lists.

Trusts (NHS boards in Scotland)

CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

- Day surgery units
- Dermatologists
- General surgeons
- General surgery
- General surgical units, directors of
- Gynaecologists
- Gynaecology departments
- Gynaecology nurses
- Maxillofacial departments
- Medical device safety officers
- Medical directors
- Obstetricians
- Obstetrics and gynaecology departments
- Obstetrics and gynaecology directors
- Obstetrics departments
- Obstetrics nurses
- Orthopaedic surgeons
- Paediatric surgeons
- Paediatric surgery, directors of
- Risk managers
- Supplies managers
- Theatre managers
- Theatre nurses
- Theatres
- Urological surgeons
- Urological surgery, directors of
- Urology departments

Independent distribution

Establishments registered with the Care Quality Commission (CQC) (England only)

- Hospitals in the independent sector
- Independent treatment centres
- Private medical practitioners

Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health's Central Alerting System (CAS) by sending an email to: safetyalerts@dh.gsi.gov.uk and requesting this facility.

Enquiries

England

Send enquiries about this notice to MHRA, quoting reference number **MDA/2015/034** or **2015/009/022/071/001**.

Technical aspects

Mr Ian Smith, MHRA

Tel: 020 3080 7306

Email: ian.smith@mhra.gsi.gov.uk

Clinical aspects

Dr S Jagdish, MHRA

Tel: 020 3080 7187

Email: sundararajan.jagdish@mhra.gsi.gov.uk

Reporting adverse incidents in England

Through Yellow Card <https://yellowcard.mhra.gov.uk/>

Northern Ireland

Alerts in Northern Ireland are distributed via the [NI SABS system](#).

Enquiries and adverse incident reports in Northern Ireland should be addressed to:

Northern Ireland Adverse Incident Centre
CMO Group,
Department of Health, Social Services and Public Safety

Tel: 028 9052 3868

Fax: 028 9052 3900

Email: NIAIC@dhsspsni.gov.uk

<http://www.dhsspsni.gov.uk/index/hea/niaic.htm>

Reporting adverse incidents in Northern Ireland

Please report directly to NIAIC using the [forms on our website](#).

Scotland

Enquiries and adverse incident reports in Scotland should be addressed to:

Incident Reporting and Investigation Centre
Health Facilities Scotland
NHS National Services Scotland

Tel: 0131 275 7575

Fax: 0131 314 0722

Email: nss.irc@nhs.net

Reporting adverse incidents in Scotland

NHS Boards and Local Authorities in Scotland – [report to Health Facilities Scotland](#).

Contractors such as private hospitals carrying out NHS work and private care homes that accept social work funded clients – [report to Health Facilities Scotland](#).

Private facilities providing care to private clients report to the [Care Inspectorate](#) and [MHRA](#).

Wales

Enquiries in Wales should be addressed to:

Healthcare Quality Division
Welsh Government

Tel: 02920 823 624 / 02920 825 510

Email: Haz-Aic@wales.gsi.gov.uk

Reporting adverse incidents in Wales

Report to MHRA through Yellow Card <https://yellowcard.mhra.gov.uk/> and follow specific advice for reporting in Wales in [MDA/2004/054 \(Wales\)](#).

MHRA is a centre of the Medicines and Healthcare products Regulatory Agency, an executive agency of the Department of Health
© Crown Copyright 2015

Addressees may take copies for distribution within their own organisations